Cargando…

Phase 1B Study of Momelotinib Combined With Trametinib in Metastatic, Kirsten Rat Sarcoma Viral Oncogene Homolog-Mutated None—Small-Cell Lung Cancer After Platinum-Based Chemotherapy Treatment Failure

We evaluated the multitargeted Janus kinase/TRAF family member associated NF-κβ activator (TANK)-binding kinase 1 (TBK1) inhibitor momelotinib combined with trametinib in 21 patients with Kirsten rat sarcoma viral oncogene homolog-mutated non—small-cell lung cancer. The maximum tolerated dose of mom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barbie, David A., Spira, Alexander, Kelly, Karen, Humeniuk, Rita, Kawashima, Jun, Kong, Shengchun, Koczywas, Marianna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6420784/ https://www.ncbi.nlm.nih.gov/pubmed/30087028 http://dx.doi.org/10.1016/j.cllc.2018.07.004

Ejemplares similares

A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer
por: Padda, Sukhmani K., et al.
Publicado: (2021)

MEK inhibitor can reverse the resistance to bevacizumab in A549 cells harboring Kirsten rat sarcoma oncogene homolog mutation
por: Wang, Yuan, et al.
Publicado: (2015)

Not All Kirsten Rat Sarcoma Viral Oncogene Homolog Mutations Predict Poor Survival in Patients With Unresectable Colorectal Liver Metastasis
por: Lin, Zhizun, et al.
Publicado: (2021)

Integration of signaling pathway and bromodomain and extra-terminal domain inhibition for the treatment of mutant Kirsten rat sarcoma viral oncogene homolog cancer
por: Hamilton, Gerhard, et al.
Publicado: (2023)

Solitary acrometastasis of the phalanx as initial presentation of an oligometastatic Kirsten rat sarcoma viral oncogene homolog-mutated lung adenocarcinoma: a case report
por: Pușcașu, Alexandra-Ioana, et al.
Publicado: (2023)

Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives
por: Li, Jia-Xin, et al.
Publicado: (2022)

Kirsten Ras* oncogene: Significance of its discovery in human cancer research
por: Tsuchida, Nobuo, et al.
Publicado: (2016)

Effect of pseudotype on Abelson virus and Kirsten sarcoma virus-induced leukemia
Publicado: (1978)

The Nanotechnology-Based Approaches against Kirsten Rat Sarcoma-Mutated Cancers
por: Andrade, Fernanda, et al.
Publicado: (2023)

Complete response to nivolumab in Kirsten rat sarcoma virus oncogene KRAS-G12C mutant metastatic lung adenocarcinoma: a case report
por: Boby, Jeffrey Mathew, et al.
Publicado: (2022)

The Effect of the Kirsten Rat Sarcoma Viral Oncogene Homolog (Kras) Proto-Oncogene, GTPase Genetic Polymorphism on the Safety and Efficacy of Bevacizumab Combination Treatment Regimens for Patients with Nonsquamous, Non-Small Cell Lung Cancer with Brain Metastases
por: Song, Zizheng, et al.
Publicado: (2022)

Clinical outcome of epidermal growth factor receptor‐tyrosine kinase inhibitors therapy for patients with overlapping kirsten rat sarcoma 2 viral oncogene homolog and epidermal growth factor receptor gene mutations
por: Zhang, Hong, et al.
Publicado: (2015)

Relationship Between (18)F-Fluorodeoxyglucose Uptake and V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Mutation in Colorectal Cancer Patients: Variability Depending on C-Reactive Protein Level
por: Lee, Jae-Hoon, et al.
Publicado: (2016)

Momelotinib: an emerging treatment for myelofibrosis patients with anemia
por: Chifotides, Helen T., et al.
Publicado: (2022)

Bioinformatics Data Mining Repurposes the JAK2 (Janus Kinase 2) Inhibitor Fedratinib for Treating Pancreatic Ductal Adenocarcinoma by Reversing the KRAS (Kirsten Rat Sarcoma 2 Viral Oncogene Homolog)-Driven Gene Signature
por: Liu, Li-Wei, et al.
Publicado: (2020)

Kirsten rat sarcoma virus protein overexpression in adenocarcinoma lung: Association with clinicopathological and histomorphological features
por: Pandey, Rahul Kumar, et al.
Publicado: (2020)

Discovering and Targeting Dynamic Drugging Pockets of Oncogenic Proteins: The Role of Magnesium in Conformational Changes of the G12D Mutated Kirsten Rat Sarcoma-Guanosine Diphosphate Complex
por: Hu, Zheyao, et al.
Publicado: (2022)

None
Publicado: (1999)

Dual-energy spectral CT characteristics in surgically resected lung adenocarcinoma: comparison between Kirsten rat sarcoma viral oncogene mutations and epidermal growth factor receptor mutations
por: Li, Meng, et al.
Publicado: (2019)

Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis
por: Pardanani, A, et al.
Publicado: (2015)

Momelotinib therapy for myelofibrosis: a 7-year follow-up
por: Tefferi, Ayalew, et al.
Publicado: (2018)

Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma
por: Ng, Kimmie, et al.
Publicado: (2018)

And then there were none
por: Christie, Agatha, 1890-1976

And then there were none
por: Silva, Jose Tiago, et al.
Publicado: (2019)

Momelotinib is a highly potent inhibitor of FLT3-mutant AML
por: Azhar, Mohammad, et al.
Publicado: (2022)

Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report
por: Rossing, Henrik H, et al.
Publicado: (2013)

Computational Screening and Analysis of Lung Cancer Related Non-Synonymous Single Nucleotide Polymorphisms on the Human Kirsten Rat Sarcoma Gene
por: Wang, Qiankun, et al.
Publicado: (2019)

Predicting Kirsten Rat Sarcoma Virus Gene Mutation Status in Patients With Colorectal Cancer by Radiomics Models Based on Multiphasic CT
por: Hu, Jianfeng, et al.
Publicado: (2022)

Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials
por: Verstovsek, Srdan, et al.
Publicado: (2023)

Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials
por: Kiladjian, Jean-Jacques, et al.
Publicado: (2023)

Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study
por: Andreyev, H J N, et al.
Publicado: (2001)

Class II histocompatibility antigen expression in human melanocytes transformed by Harvey murine sarcoma virus (Ha-MSV) and Kirsten MSV retroviruses
Publicado: (1986)

Effective management of advanced colon cancer genotyping microsatellite stable/microsatellite instable-low with Kirsten rat sarcoma viral oncogene mutation using nivolumab plus ipilimumab combined with regorafenib and irinotecan: A case report
por: Cui, Yingqiang, et al.
Publicado: (2021)

Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies
por: Mesa, Ruben A., et al.
Publicado: (2023)

P1062: INDIRECT TREATMENT COMPARISON OF MOMELOTINIB VS FEDRATINIB SAFETY IN PATIENTS WITH MYELOFIBROSIS
por: Palandri, Francesca, et al.
Publicado: (2023)

None Too Much Quarantine
Publicado: (1885)

A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia
por: Verstovsek, Srdan, et al.
Publicado: (2017)

Inhibition of lung adenocarcinoma cells by insulin-like growth factor-I receptor and Kirsten rat sarcoma mutations: A mutation analysis with antisense oligodeoxynucleotide
por: Li, Shaoming, et al.
Publicado: (2015)

Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis
por: Mesa, Ruben, et al.
Publicado: (2022)

With charity toward none : a fond look at misanthropy
por: King, Florence
Publicado: (1993)

Cannot write session to /tmp/vufind_sessions/sess_456b5d1pu8a8eb9sf51nl720ks